BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:20 PM
Feb 20, 2007
 |  BC Extra  |  Company News

Dyax, Genzyme end DX-88 deal

DYAX said late Tuesday that it and partner GENZ mutually agreed to terminate a 2003 joint development and commercialization deal for DX-88 to treat hereditary angioedema (HAE). DYAX said the news won't affect its development and regulatory timelines for the yeast-derived...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >